key: cord-0926491-eve912qt
authors: Jacob, Elizabeth; Avery, Amanda
title: Energy‐restricted interventions are effective for the remission of newly diagnosed type 2 diabetes: A systematic review of the evidence base
date: 2021-05-15
journal: Obes Sci Pract
DOI: 10.1002/osp4.504
sha: eeac310d401a26e99d076d92271a3f38d9c33090
doc_id: 926491
cord_uid: eve912qt

BACKGROUND: Type 2 diabetes (T2D) is a chronic, progressive disease. Caloric restriction and subsequent weight loss have been associated with both improvements and, in some cases, remission of T2D. AIM: To systematically review the safety and effectiveness of calorie‐restricted diets on weight change and the remission of T2D. METHODS: Electronic databases were searched. Intervention trials including a calorie restriction, published between 2010 and 2020, evaluating the remission of T2D (HbA1c <6.5% without diabetes medication) were selected. Risk of bias was assessed. RESULTS: Eight trials met inclusion criteria including four randomized controlled and four single‐arm trials. Three controlled trials found greater remission in the calorie‐restricted arm (p < 0.05). A recent diagnosis of diabetes was associated with higher remission rates (75%–80%) with an inverse association between duration of diabetes and rate of remission (r = −0.94). A higher level of remission was observed with greater calorie restriction in non‐new diagnosis studies. Greater weight loss was associated with increasing rates of remission (r = 0.83). No reported adverse events led to withdrawal from trials. There was great heterogeneity in study design. CONCLUSION: Remission rate of T2D achieved through calorie restriction is high and similar to that reported in the bariatric surgery literature. Remission should be the aim at diagnosis and calorie restriction could be used to achieve this. The target weight loss should be >10% body weight in people with obesity. More research is needed into the optimum level of calorie restriction and the support required for long‐term remission. National guidelines should be updated to reflect recent evidence.

The prevalence of type 2 diabetes (T2D) has increased over the past 20 years with global prevalence rates (in people aged 20-79 years) reaching 9.3% in 2019. 1 A more recent concern is that T2D is a risk factor for a worse outcome in those with COVID-19 infection. The mortality rate for those with diabetes or uncontrolled hyperglycemia was found to be more than four times higher than for those without either of those risk factors. 2 People with T2D have been found to have significantly higher risk of respiratory distress syndrome and multiple organ injury. 3, 4 The economic costs of T2D are increasing as well as the immeasurable pain and suffering of those with the condition. [5] [6] [7] [8] The national guidance on the management of T2D mentions a few sentences about dietary advice, with the bulk of the information relating to medications and algorithms to progress through when treating worsening hyperglycemia. 9 The aim of remission of diabetes is not specifically discussed anywhere in this guideline. Eligibility for bariatric surgery is discussed in the national guidelines for obesity management for those with new-onset T2D with a body mass index (BMI) greater than 30 or at a lower BMI if people are of Asian origin. 10 The 7-year cumulative incidence of achieving partial/complete or prolonged remission in people newly diagnosed with T2D on no diabetic medication with standard care was 1.60%. 11 A recent review by Hallberg et al. 12 examined reversal of diabetes by three methods: bariatric surgery, carbohydrate-restricted diets, and low-calorie diets. There have been a number of systematic reviews in the field of bariatric surgery 13, 14 and carbohydrate restriction 15, 16 for the treatment of T2D. Kelly and colleagues 17 conducted a review of studies that examined lifestyle modifications targeting the remission of T2D. However, their definition of remission was broad and included normalization of fasting plasma glucose, HbA1c, an oral glucose tolerance test and normalization of β cell function. Taylor 18 summarized the rationale for the DiRECT study, but the article did not systematically review all the published evidence in the field of energy restriction and diabetes remission.

Lim et al. 19 demonstrated that insulin resistance and pancreatic β-cell failure could be reversed with an energy-restricted diet (600 kcal/day). There was an associated decrease in liver and pancreatic triacylglycerol stores. Steven et al. 20 demonstrated that an 8-week energy-restricted diet (624-700 kcal/day) produced a sustainable normalization of fasting plasma glucose to less than 7.0 mmol/L in 40% of the study population at 6 months. Responders were noted to have a shorter duration of diabetes (3.8 ± 1.0 vs. 9.8 ± 1.6 years, p = 0.007).

There has been much debate about the definition of reversal and remission of T2DM. Buse et al. 21 suggested a partial remission to be defined as an HbA1c less than 6.5% and fasting glucose of 5.6-6.9 mmol/L for at least 1-year duration without pharmacological therapy.

Complete remission was defined as having HbA1c in the normal range and fasting glucose less than 5.6 mmol/L for 1 year without pharmacological therapy. A simpler HbA1c criteria based on the American diabetes guidelines of diagnosis of diabetes with remission if HbA1c <5.7% and improvement with HbA1c 5.7%-6.5% with no hypoglycemic medication and a duration of at least 1 year has also been proposed. 22 Some authors 12 have removed metformin from the list of medications for glycemic control as this drug has a role in prevention. 23 For the purposes of this review, as some studies included were of short duration and there is such heterogeneity of definition of remission between studies, a complete or partial remission was defined as an HbA1c less than 6.5%/48 mmol/mol without the use of diabetes medication.

The aim of this review was to assess the safety and effectiveness of energy-restricted interventions in achieving remission of T2D. Scalable interventions for the remission of T2D are urgently needed and there has been no in-depth review of energy restriction conducted for this purpose with a uniform definition of remission. The primary outcome measure was levels of HbA1c less than 6.5%/48 mmol/mol with no hypoglycemic medications in energy-restricted dietary interventions. Secondary outcome measures were weight change, reduction in HbA1c levels, and serious adverse events.

A literature search was conducted using the electronic databases of PubMED and Wiley Online. The following search terms were used: #1: "Diabetes" OR "Diabetes Mellitus" OR "Type 2 Diabetes" OR "Non Insulin Dependent Diabetes" OR "T2DM" or "NIDDM"; #2: "Calorie restricted" OR "Very low calorie diet" OR "Lifestyle intervention" OR "Intensive Lifestyle"; #3: "Remission" or "Reversal".

An advanced electronic search was performed and filters were applied to include only journal articles, publications in the English language, species to be human only, adults and searches were limited to the last 10 years. The final search was conducted on 30 January 2021. The reference lists of relevant publications were hand searched to find any relevant articles. The titles and abstracts were screened against the inclusion and exclusion criteria listed in Table 1 .

Full-text articles of the short-listed articles were then further screened. Inter-library loans were undertaken when necessary to locate full text articles. A second reviewer independently assessed papers for final eligibility and any disagreement was discussed and resolved.

Data were extracted by a single reviewer. The data included author, year, country of origin, duration of study, number of participants, male/female ratio, number of completers of each arm of trial, baseline weight, baseline HbA1c%/mmol/mol, mean duration since diagnosis (unless stated as median), inclusion criteria, intervention and control details, outcome measures of interest and serious adverse events. HbA1c % and mmol/mol were converted where possible, so both could be presented. Mean weight loss and standard deviation and mean change in HbA1c % were calculated from supplementary information for one study. 24 The Pearson correlation coefficient (r-value) was calculated for a number of variables in the collated results. JACOB AND AVERY -607

The study was reported according to PRISMA statement 25 (see Figure S1 ). All supplementary tables are available by contacting the corresponding author.

The Downs and Black 26 quality assessment tool was used to assess the risk of bias. This tool was chosen as it can be used to compare randomized and non-randomized controlled trials.

Preliminary searches found a paucity of randomized controlled trials in this field in the last 10 years, so the decision was made to include single-arm intervention trials even though they would be at higher risk of bias, to increase the breadth of data to analyze. The literature search generated 660 results. After removal of duplicates, 641 records were screened. Seventeen studies were assessed and finally eight studies were included (see Figure 1 ). The assessment of bias has been summarized in Table S1 , with original scoring in Table S2 .

Four publications of randomized controlled trials were found including a 2-year update for one of the studies. Two of these were retrospective analyses of data. Four single-arm studies were also included. The total sample size from all of the eight studies was 5764 participants. Energy restriction ranged from prescribed periods of 600 kcal/day to individualized levels between 1200 and 1800 kcal/ day for the entire study duration. The length of time since diagnosis ranged from new diagnosis to 5 years. The studies took place in the United Kingdom, India, United States, Denmark, Thailand, and Qatar.

Detailed characteristics including interventions and controls (if applicable) for all studies have been described in Table 2 .

Lean et al. 27 Weaknesses include the energy restriction only occurring for the first 4 months of the study and the location of much of the delivery being a teaching hospital which may not be representative of the care that the average patient with T2D is able to access. Also, the secondary analysis was not powered to assess T2D remission rates. Remission rates in this study were larger at 23% for the intervention group than 7% for the control group, but the difference was not statistically significant (p = 0.08).

A retrospective analysis was conducted using the results of the Look AHEAD trial. 30, 31 The trial lasted 4 years. Energy restriction ranged from 1200 to 1800 kcal/day in the intervention group and meal replacements were offered. Physical activity was increased to 175 min/week. Weight loss at year 1 was 8.6% in the intervention group compared to 0.7% in the control group (p < 0.001). In year 4, weight loss was 4.7% in the intervention group compared with 0.8% in the control group (<0.001). Strengths of the study again include the number of participants (n = 5145) and the duration of the study. This was also an innovative and pivotal study in reframing T2D from a chronic progressive condition to one with a possibility of remission. The analysis excluded participants who underwent bariatric surgery. However, they also excluded participants with missing outcome data allowing for potential attrition bias. The patients were extensively screened for their potential to lose weight, meaning the results may not be applicable to the general population with T2D. Also, as it was a retrospective analysis, a power calculation was not done. At year 1, 11.5% in the intervention group compared to 2% in the control group achieved remission (p < 0.001). At year 4, this was 7.3% in the intervention group and 2% in the control group (p < 0.001).

A single-arm study to assess the efficacy, safety, and durability of a very-low-calorie diet (VLCD) in Thai patients for the remission of T2D was undertaken by Umphonsathien and colleagues. 35 The authors recruited members of staff at a hospital. The intervention involved a run-in of 2 weeks of total diet replacement of 600 kcal/day to assess compliance. If this was tolerated, it was followed by 8 weeks of 600 kcal/day, then a stepwise calorie increase with week 9-800 kcal/day, week 10-1000 kcal/day, week 11 -1200 kcal/day, and

week 12-1500 kcal/day. Mean weight loss of 9.5 kg was achieved in the study group at 14 weeks. Strengths include the clear outcomes and aims of the study and that a power calculation was done.

Weaknesses include the small sample size (n = 20), no control group, the recruitment of hospital staff who may not be representative of the typical population with T2D and participants' level of compliance was unclear. Rates of remission were 75% at 14 weeks, and fell to 30% and 6 months and 20% at 1 year.

A 6-month single-arm study was undertaken in participants with newly diagnosed diabetes to assess the effect of a program including a 500 kcal/day deficit and exercise (walking) on the rate of remission. 34 Mean weight loss at 6 months was 9.7 kg in the participants. Sarathi et al. 29 conducted a single-arm study on young adults with newly diagnosed T2D to assess the reversibility of the condition.

Calorie intake was limited to 1500 kcal/day and participants under- remission. The calorie restriction (1500 kcal) was not as low as the DiRECT study or Umphonsathien et al. 35 Bhatt et al. 24 conducted a single-arm study on the use of 1000 kcal/day total diet replacements for 12 weeks. Moderate aerobic and resistance intensity exercise was advised from week 2. Mean weight loss at 12 weeks was 6.8 kg. This was a poorly conducted and reported study. There were no clearly described aims and outcomes.

There was no control arm and the sample size was small (n = 12). It was unclear how participants were recruited. Fifty percent of participants achieved remission of diabetes at 12 weeks.

Three factors varied in the intensity of the intervention: the level of calorie restriction, the duration of calorie restriction, and the addition of supervised structured physical activity. A comparison of the intensity of the intervention is tabulated in Table S4 . An average adult's calorie intake is assumed to be 2250 kcal/day (males 2500 kcal and females 2000 kcal), 37 the calorie deficit has been calculated as the difference between average calorie intake and the calorie intake of the intervention. This is not accounting for cultural differences in calorie intake or the number of males and females in each study.

One of the most intense calorie restrictions was in the DiRECT study, 27, 28 but there was also a maintenance plan beyond the first intervention. Of note, weight losses had decreased on average by year 2 from −10.0 to −7.6 kg. The DIADEM-1 study 36 combined a strict calorie restriction with physical exercise and achieved the highest total weight loss at the end of a study. Umphonsathien et al. 35 had the most severe calorie restriction but there was no intervention beyond 14 weeks and weight loss results were not collected beyond this. There were relatively low calorie restrictions by Ades et al. 34 and Sarathi et al. 29 but impressive weight losses. There were ongoing weight losses in the second year for Sarathi et al. 29 Both these studies used physical activity raising the possibility of its importance in remission maintenance. However, contradictory to this hypothesis is that Ried-Larsen et al. 32 used structured exercise as part of the intervention with minimal weight loss and a non-statistically significant reduction in remission in the control group. The calorie restriction only lasted 4 months in this study, and it is possible that this was not a strong enough intervention. The optimum balance of caloric restriction and exercise for diabetes remission and maintenance is an important question that needs further assessment.

Weight loss was expressed as a percentage by Gregg et al. 30 so it is difficult to directly compare with the other studies. Figure 1 shows weight loss in kilograms plotted against remission rates for the intervention groups as well as the control groups. Gregg et al. 30 was excluded from this as weight loss was presented in percentage terms. Increased weight loss appears to be associated with increased rates of remission (r = 0.83). The largest mean weight losses were made by Lean et al. 27 in year 1 at 10 kg, Taheri et al. 36 in year 1 at 12.0 kg, Ades et al. 34 at 9.7 kg at just 6 months, and Umphonsathien et al. 35 at just 14 weeks with 9.5 kg. The remission rate fell rapidly over the first year for Umphonsathien et al. 35 and by just over 10% for Lean et al. 28 Lean et al. 27 found that the odds ratio per kilogram weight loss for attaining remission was 1.32 (95% CI:

1.23-.41; P < 0.0001). Gregg et al. 30 found that the probability of 1-year remission was the highest among those who lost greater than 6.5% weight (16.4%; 95% CI: 14.5%-18.6%). Remission of diabetes was possible for 70% of those who maintained more than 15 kg weight loss in the DiRECT study 27 ; however, only 24% was able to achieve this weight loss in the first year despite a severe calorie restriction. Sarathi et al. 29 found that no patients who achieved remission and maintained or decreased from their 3-month weight loss had recurrence of T2D. Gregg et al. 30 found that one-third of those who had a remission returned to diabetes every year. The associated weight gain was not reported.

This data is presented in Table S5 . The studies with higher baseline

HbA1c level had a greater fall (Sarathi et al. 29 and Bhatt et al. 24 ). Gregg et al. 30 did not present data on changes in HbA1c levels. Interestingly, Ried-Larsen et al. 32 found an increase in HbA1c level in both the intervention and control groups at 24 months. The 12-month data from this study, 33 showed a change of −0.31% in the intervention group and −0.08% in the control group (p = 0.15). As some patients developed remission, presumably in those that did not, there was an overall increase in HbA1c to account for this mean rise in each arm.

There is no clear association between baseline HbA1c levels and remission rate (r = 0.36) ( Figure S2 ). Gregg et al. 30 found an association between low baseline HbA1c levels and remission rates (p < 0.001). Umphonsathien et al. 35 and Sarathi et al. 29 found no association between baseline HbA1c and remission rates. Of note, Ried-Larsen et al. 32 and Taheri et al. 36 had particularly low levels of baseline HbA1c in the intervention and control groups. This may explain the relatively low levels of mean weight loss achieving better remission rates in these control groups (7% and 12%) compared with the control groups in the other studies. This may also have contributed to the lack of statistical significance between the intervention and control groups for Ried-Larsen et al. 32 Ethnically, populations such as Thai may have lower mean body weights. Lean et al. 28 found no association between baseline BMI and likelihood of remission at 24 months. Umphonsathien et al. 35 and Sarathi et al. 29 found no association between baseline weight and remission rates. However, Gregg et al. 30 did find an association with lower BMI and likelihood of further remission (p < 0.001). Figure 2 shows an inverse association between the duration of diabetes and the remission rate (r = −0.94). The duration of diabetes was a mean value for all studies, except Umphonsathien et al. 35 Gregg et al. 30 and Bhatt et al. 24 who presented median values. The studies with the longest duration since diagnosis were Gregg et al. 30 and Ried-Larsen et al. 32 This may have contributed to the lower remission rates in both of these studies. There was no association between the duration of diabetes within 6 years from diagnosis inclusion criteria in the DiRECT study. However, Figure 2 shows the highest rates of remission were achieved in those newly diagnosed and the mean time since diagnosis was 3 years for both arms of the DiRECT study. Both studies with participants having newly diagnosed diabetes (Sarathi et al. 29 ; Ades et al. 34 ) were single-arm studies with evidence of bias (Table S2 ). Gregg et al. 30 found a statistically significant association between fewer years since diagnosis and remission rates (p < 0.001). Bhatt et al. 24 found that responders had a shorter duration of diabetes than non-responders (1.5 vs. 4.0 years), but no statistical analysis was carried out. In contrast, Umphonsathien et al. 35 found no association between diabetes duration and remission rates.

Taheri et al. 36 found fewer serious adverse events in the intervention arm compared to the control arm as did Lean et al. 28 who also reported statistical significance with p = 0.029 (see Table 3 ). There F I G U R E 2 Remission rate compared with duration of diabetes Lean et al. 28 Year 2 results n = 9 events in 6 participants One non-fatal MI in a patient that did not attend for review. None led to withdrawal from the trial. n = 22 events in 16 participants x2 cerbrovascular accident, toe amputation, aortic aneurysm rupture, sudden death.

Bhatt et al. 24 Not described.

Sarathi et al. 29 Not described.

Gregg et al. 30 Not described for subpopulation examined in this analysis.

Ried-Larsen et al. 32 Johansen et al. 33 n = 1 Atrial fibrillation. were no significant differences in adverse events between the two groups reported by Gregg et al. 30 Bhatt et al. 24 Sarathi et al. 29 and

Ades et al. 34 did not describe adverse events. Umphonsathien et al. 35 had no adverse events and Reid-Larsen et al. 32 had one serious adverse event in the intervention group (an episode of atrial fibrillation), but this was not statistically significant (p = 1.00). There were few adverse events described that related to the interventions and none that led to withdrawal from the studies.

This review has found that dietary energy restriction is an effective treatment strategy for the remission of T2D with higher rates 11.5% and 75%. 27, 29, 30, 35, 36 Energy restriction as a method of diabetes reversal has also been found to be safe with relatively few serious adverse events reported.

Bariatric surgery has been recommended as a treatment for people with T2D and a BMI of 30 kg/m 2 or above, or at a lower level if of Asian origin and not achieving treatment targets. 38 year. Courcoulas et al. 41 reported that the medical intervention was based on the Look AHEAD trial, but the remission rate was much lower than that reported by Gregg et al. 30 Parikh et al. 39 mentioned themselves that they could have integrated more extensive lifestyle changes into the medical weight management arm.

A 7-year multicenter longitudinal study 42 found that the rate of remission was 60.2% for Roux-en-Y gastric bypass and 20.3% for laparoscopic gastric banding in patients with T2D. The authors reported that lifestyle programs are often the first-line recommendations for obesity management, but are largely ineffective and when successful, weight loss is rarely sustained. However, the outcomes in the lifestyle arms of bariatric surgery are much below those of studies primarily focused on remission of diabetes through caloric restriction in this review. This suggests the intensity of caloric-restriction intervention may be too low in these bariatric trials. The outcomes in many of the calorie-restricted studies in this review were comparable to the remission rates achieved by bariatric surgery.

Carbohydrate restriction has also been used as a treatment for T2D, but meta-analysis has shown little effect on glycemic control beyond the short term. 43 However, a more recent study 44 Ten percent weight loss seems a reasonable initial target for remission of diabetes and was the minimum weight loss that resulted large levels of remission in a number of studies. [27] [28] [29] [34] [35] [36] In fact, in the DiRECT study with a baseline weight of approximately 100 kg in both groups, of those losing greater than 10 kg, 64% achieved remission at 24 months.

For 5-10 kg, it was 29%, and for less than 5 kg, it was 5% remission.

Remission was more likely with greater weight loss from baseline with adjusted odds ratio 1.2 per kg loss. The most impressive remissions in the current review were achieved by Sarathi et al. 29 and Ades et al. 34 who both conducted studies on patients with newly diagnosed diabetes. The calorie restrictions in both studies were relatively low, but perhaps more easily maintained.

Kelly and colleagues 17 found that when they classified lifestyle interventions into therapeutic (600-1500 kcal total daily intake), the weighted mean remission was 49.4% versus subtherapeutic (800-1500 kcal total daily intake), where the weighted mean remission was 6.9%. The distinction between therapeutic and subtherapeutic dosing was based on treatment goals and whether the intervention produced remission in a substantial proportion of participants. There is clearly an overlap in calorie intake in both groups. They did not examine the relationship between time from diagnosis of T2D with remission rates. The authors noted that the dosing intensity required to achieve remission of T2D was much higher than that required to prevent it. It is therefore plausible that a lower intensity intervention may be adequate to achieve remission earlier in the pathogenesis of the disease (i.e., at diagnosis) where there is less β cell damage. In an era of COVID-19 infection where the risk of diabetes is even greater 616than previously thought, would the information that a new diagnosis of diabetes is likely reversible for a limited number of years be the motivating factor to help patients lose and maintain weight loss? This is an interesting area for future research.

Lean et al. 27 

Recommendations for practice based on the findings of this review are to offer patients with a diagnosis of diabetes within the last 6

years an opportunity to achieve remission. The target weight loss should be at least 10% of body weight in individuals with sufficient overweight and obesity. The high levels of remission of newly diagnosed diabetes were a surprising finding, as this was not reported in the highly publicized DiRECT trial. Therefore, weight loss should be particularly encouraged as a first-line approach for those with a new diagnosis of T2D. The favored method should reflect patient preferences, but options should include an energy-restricted diet. Total meal replacement methods have been very effective in a number of studies in achieving this in the short and medium terms, but are not the exclusive route to remission. More research is needed to establish the optimal intensity in terms of energy restriction and duration, and the role of exercise for the maintenance of remission. National guidelines should be updated to reflect recent evidence.

Rupesh Tailor provided assistance in the statistical analysis. He had no role in the execution or drafting of this article. This systematic review used publicly accessible literature as evidence and did not collect any deeply personal, sensitive or confidential information from participants.

International Diabetes Federation. 2021. Diabetesatlas.org

ATLAS9e-final-web.pdf#page=38&zoom=auto>

Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States

Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes

Factors leading to high morbidity and mortality of COVID -19 in patients with type 2 diabetes

Economic costs of diabetes in the U. S

Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries: a systematic review

Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: a systematic review

Relationship between diabetic neuropathic pain and comorbidity. Their impact on pain intensity, diabetes complications and quality of life in patients with type-2 diabetes mellitus

NICE. Overview | Type 2 Diabetes in Adults: Management | Guidance | NICE. 2020a. Nice.org.uk

Overview | Obesity: Identification, Assessment and Management | Guidance | NICE. 2020b. Nice.org

Incidence of remission in adults with type 2 diabetes: the diabetes & aging study

Reversing type 2 diabetes: a narrative review of the evidence

The long-term effects of bariatric surgery for type 2 diabetes: systematic review and meta-analysis of randomized and non-randomized evidence

Bariatric surgery as a treatment for type 2 diabetes mellitus: a narrative review

Efficacy of low carbohydrate diet for type 2 diabetes mellitus management: a systematic review and meta-analysis of randomized controlled trials

Effects of lowcarbohydrate-compared with low-fat-diet interventions on metabolic control in people with type 2 diabetes: a systematic review including GRADE assessments

Type 2 diabetes remission and lifestyle medicine: a position statement from the American College of lifestyle medicine

Calorie restriction for long-term remission of type 2 diabetes

Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia

Very low-calorie diet and 6 Months of weight stability in type 2 diabetes: pathophysiological changes in responders and nonresponders

How do we define cure of diabetes? Diabetes Care

Which criteria should be used to define type 2 diabetes remission after bariatric surgery

On behalf of the diabetes prevention program research group. Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the diabetes prevention program and diabetes prevention program outcomes study

Effect of a low-calorie diet on restoration of normoglycemia in obese subjects with type 2 diabetes

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions

Primary care-led weight management for remission of type 2 diabetes (DiRECT): an openlabel, cluster-randomised trial

Durability of a primary careled weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial

High rates of diabetes reversal in newly diagnosed Asian Indian young adults with type 2 diabetes mellitus with intensive lifestyle therapy

Association of an intensive lifestyle intervention with remission of type 2 diabetes

The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it*

Type 2 diabetes remission 1 year after an intensive lifestyle intervention: a secondary analysis of a randomized clinical trial

Effect of an intensive lifestyle intervention on glycemic control in patients with type 2 diabetes

Remission of recently diagnosed type 2 diabetes mellitus with weight loss and exercise

Immediate and long-term effects of a very-low-calorie diet on diabetes remission and glycemic control in obese Thai patients with type 2 diabetes mellitus

Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial

The National Food guide: development of dietetic criteria and nutritional characteristics

Bariatric surgery: an IDF statement for obese Type 2 diabetes

Randomized pilot trial of bariatric surgery versus intensive medical weight management on diabetes remission in type 2 diabetic patients who do NOT meet NIH criteria for surgery and the role of soluble RAGE as a novel biomarker of success

Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. Diabetologia

Surgical vs medical treatments for type 2 diabetes mellitus

Long-term outcomes following bariatric surgery

Low-carbohydrate diets and type 2 diabetes treatment: a meta-analysis of randomized controlled trials

Author Correction: effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 Year: an open-label, non-randomized, controlled study

Long-term effects of a novel Continuous remote care intervention including nutritional ketosis for the management of type 2 diabetes: a 2-year nonrandomized clinical trial

Behaviour change, weight loss and remission of Type 2 diabetes: a communitybased prospective cohort study

Energy-restricted interventions are effective for the remission of newly diagnosed type 2 diabetes: a systematic review of the evidence base

The authors have no conflict of interest.

Elizabeth Jacob was involved in the initial data collection, analysis and interpretation. Amanda Avery was involved in critical revision of the article. Both authors contributed substantially to the intellectual content during manuscript draft or revision. All authors approved the manuscript and the submission.

https://orcid.org/0000-0003-0353-9530